Cargando…

Drug-induced CYP induction as therapy for tacrolimus intoxication

Management of calcineurin inhibitor (CNI) therapy in kidney transplant recipients may be complicated due to polypharmacy. As CNI undergo extensive metabolism by cytochrome-P450 enzymes (CYP), drug-mediated CYP inhibition poses a risk for elevated CNI blood concentrations. Here, we report on 2 kidney...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoppe, John M., Holderied, Alexander, Schönermarck, Ulf, Vielhauer, Volker, Anders, Hans-Joachim , Fischereder, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dustri-Verlag Dr. Karl Feistle 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153279/ https://www.ncbi.nlm.nih.gov/pubmed/35651717 http://dx.doi.org/10.5414/CNCS110744

Ejemplares similares

Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden
por: Schönermarck, Ulf, et al.
Publicado: (2021)

Membrane and centrifugal therapeutic plasma exchange: practical difficulties in anticoagulating the extracorporeal circuit
por: Seibt, Tobias, et al.
Publicado: (2014)

Renal co-morbidity in patients with rheumatic diseases
por: Anders, Hans-Joachim, et al.
Publicado: (2011)

Humoral immunity to SARS-CoV-2 vaccination in haemodialysis patients: (Response to: Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.)
por: Hasmann, Sandra, et al.
Publicado: (2021)

Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection
por: Kemmner, Stephan, et al.
Publicado: (2020)

Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report
por: Schiopu, Sanziana R. I., et al.
Publicado: (2021)

Effect of Apheresis for ABO and HLA Desensitization on Anti-Measles Antibody Titers in Renal Transplantation
por: Schönermarck, Ulf, et al.
Publicado: (2011)

Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange
por: Sagmeister, Michael S., et al.
Publicado: (2018)

Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus
por: Shimizu, Hiromichi, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis
por: Zhou, Tianbiao, et al.
Publicado: (2019)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2023)

Successful induction of granulomatosis with polyangiitis with tacrolimus
por: Ramachandran, R., et al.
Publicado: (2015)

Optimizing Mouse Surgery with Online Rectal Temperature Monitoring and Preoperative Heat Supply. Effects on Post-Ischemic Acute Kidney Injury
por: Marschner, Julian A., et al.
Publicado: (2016)

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients
por: Yang, Yilei, et al.
Publicado: (2021)

“Point of no return” in unilateral renal ischemia reperfusion injury in mice
por: Holderied, Alexander, et al.
Publicado: (2020)

Induction of CYP3A activity by dexamethasone may not be strong, even at high doses: insights from a case of tacrolimus co-administration
por: Ohno, Yoshiyuki, et al.
Publicado: (2023)

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy
por: Zhang, Chengning, et al.
Publicado: (2020)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

Influence of CYP3A5 polymorphism on tacrolimus drug dosing in Indian renal allograft recipients: initial experience
por: Patel, Mohan, et al.
Publicado: (2014)

Severe Acute Kidney Injury in Cardiovascular Surgery: Thrombotic Microangiopathy as a Differential Diagnosis to Ischemia Reperfusion Injury. A Retrospective Study
por: Grigorescu, Melissa, et al.
Publicado: (2020)

Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation
por: Åsberg, Anders, et al.
Publicado: (2013)

Long-lasting renal dysfunction following tacrolimus induction therapy in ulcerative colitis patients
por: Cha, Na, et al.
Publicado: (2022)

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
por: Chen, Lucy, et al.
Publicado: (2018)

CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients
por: Yamamoto, Yuki, et al.
Publicado: (2020)

Influence of CYP3A5 and ABCB1 Polymorphism on Tacrolimus Drug Dosing in South Indian Renal Allograft Recipients
por: Fernando, M. Edwin, et al.
Publicado: (2019)

Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study
por: Ito, Ayumi, et al.
Publicado: (2016)

Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis
por: Numa, Keijiro, et al.
Publicado: (2023)

Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection
por: Füessl, Louise, et al.
Publicado: (2022)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients
por: Hernandez, Savine, et al.
Publicado: (2023)

Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2017)

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020)

Effects of CYP3A5 Genotypes on Thrombocytopenia in Liver Transplantation Patients Treated with Tacrolimus
por: Guo, Zhe, et al.
Publicado: (2023)

Regulated necrosis-related molecule mRNA expression in humans and mice and in murine acute tissue injury and systemic autoimmunity leading to progressive organ damage, and progressive fibrosis
por: Honarpisheh, Mohsen, et al.
Publicado: (2016)

Rapid Induction Therapy with Oral Tacrolimus in Elderly Patients with Refractory Ulcerative Colitis Can Easily Lead to Elevated Tacrolimus Concentrations in Blood: A Report of 5 Cases
por: Kawamura, Haruna, et al.
Publicado: (2017)

Drugs and pharmaceuticals: management of intoxication and antidotes
por: Smith, Silas W.
Publicado: (2010)

The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients
por: Hiraoka, Sakiko, et al.
Publicado: (2015)

Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population
por: Hadjipanagi, Despina, et al.
Publicado: (2014)

Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome
por: Li, Min, et al.
Publicado: (2018)

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living‐donor Egyptian kidney transplanted patients
por: Wanas, Hanaa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ff970btqn55msqn9gc2n3jn9th